Kura Oncology (NASDAQ:KURA) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Kura Oncology (NASDAQ:KURA) announced its quarterly earnings data on Thursday. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20), FiscalAI reports. The firm had revenue of $17.34 million for the quarter, compared to analysts’ expectations of $34.71 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%.

Here are the key takeaways from Kura Oncology’s conference call:

• Komzifti launched after FDA approval and generated $2.1M in late‑2025 revenue, with rapid uptake: ~84% of private payers established coverage within 90 days, a two‑day average prescription‑to‑payer decision via KuraConnect, and some payers implementing step edits that require Komzifti before a competitor.
• Komzifti is listed in the FDA Orange Book with patent protection through July 2044, which the company says strengthens the long‑term value of the franchise as it expands into frontline and combination settings.
• Kura is executing an extensive development plan—pivotal KOMET‑017 (two independently powered frontline trials), multiple combination programs (venetoclax, FLT3 inhibitors), and solid‑tumor efforts including darlifarnib—with multiple data readouts planned in 2026 and a phase‑3 top‑line readout expected in 2028.
• Commercial launch and expanded development increased costs: Q4 2025 net loss widened to $81M (vs. $19.2M a year earlier), with higher R&D ($64.4M) and SG&A ($39.1M) contributing to the loss.
• Kura ended 2025 with $667.2M in cash and short‑term investments and expects collaboration revenue and ~<$180M in anticipated milestones to fund its ziftomenib AML program through the first KOMET‑017 phase‑3 results in 2028.

Kura Oncology Trading Up 2.9%

NASDAQ:KURA traded up $0.25 during mid-day trading on Friday, reaching $8.76. 601,970 shares of the company’s stock traded hands, compared to its average volume of 1,461,114. The company has a 50 day moving average price of $8.79 and a 200-day moving average price of $9.38. The firm has a market capitalization of $762.30 million, a price-to-earnings ratio of -3.53 and a beta of 0.22. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. Kura Oncology has a 12-month low of $5.41 and a 12-month high of $12.49.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on KURA. Barclays restated an “overweight” rating and issued a $28.00 price objective (up from $11.00) on shares of Kura Oncology in a report on Monday, November 24th. Zacks Research upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. Leerink Partners set a $20.00 price objective on Kura Oncology and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Wall Street Zen cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $27.71.

Key Stories Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI commercial launch showing early traction — Kura reported $2.1M of product revenue from ~5 weeks of sales, rapid payer coverage (~80% of private payers aligned to label within 90 days) and Orange Book patent listings through 2044, supporting longer-term market potential. Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Large addressable opportunity and upcoming catalysts — Management highlighted a potential multi‑billion dollar AML market opportunity and multiple 2026 clinical milestones (pivotal KOMET‑017 Phase 3 enrollment, KOMET‑007 updates, combination data), which could be value inflection points if positive. Kura Oncology anticipates $7B AML opportunity
• Positive Sentiment: Strong cash & collaboration support — Kura ended 2025 with ~$667M cash + $180M expected collaboration payments (Kyowa Kirin milestones), which management says funds operations into late 2027 and supports development through initial pivotal Phase 3 topline data. Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst coverage remains generally constructive though mixed — Wedbush trimmed its price target from $38 to $36 but maintained an Outperform rating, leaving sizeable upside vs. the current price; other firms still show buy/outperform views. This keeps analyst interest high but introduces some near‑term variability. Wedbush price target note
• Neutral Sentiment: Minor corporate items — Board compensation committee granted inducement stock options to four new hires (44,700 shares total), a routine hiring tool that slightly dilutes but is standard for biotech recruiting. Inducement Grants press release
• Negative Sentiment: Q4 earnings and revenue misses — Kura reported Q4 EPS of $(0.92) (worse than estimates) and total revenue of $17.3M vs. consensus ~ $34–35M, driven by lower collaboration revenue recognition. The miss is a clear near‑term negative driving selling pressure. Earnings press release / transcript
• Negative Sentiment: Rising operating losses and commercialization costs — R&D and SG&A grew meaningfully (advancing combos and commercial build), producing a wider net loss ($81M Q4) and heavier near‑term burn despite cash runway, which could pressure sentiment until revenue growth proves durable. Q4 financial detail
• Negative Sentiment: Safety profile and utilization risks — KOMZIFTI carries boxed warning for differentiation syndrome and notable rates of QTc prolongation and serious AEs; these safety considerations may limit uptake or complicate broader frontline/combo use, creating execution risk. Early commercial summary with safety notes

Insider Activity

In other Kura Oncology news, insider Teresa Brophy Bair sold 11,208 shares of the company’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $94,819.68. Following the completion of the transaction, the insider directly owned 226,931 shares in the company, valued at approximately $1,919,836.26. This represents a 4.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian T. Powl sold 6,414 shares of Kura Oncology stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $54,262.44. Following the sale, the insider directly owned 183,275 shares in the company, valued at $1,550,506.50. The trade was a 3.38% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 59,794 shares of company stock valued at $537,176. 6.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently bought and sold shares of the business. State Street Corp increased its stake in shares of Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after purchasing an additional 1,587,959 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in Kura Oncology by 101.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after buying an additional 1,121,228 shares in the last quarter. Renaissance Technologies LLC raised its stake in Kura Oncology by 111.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock valued at $19,020,000 after buying an additional 965,256 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Kura Oncology by 36.6% in the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after acquiring an additional 820,020 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its stake in shares of Kura Oncology by 63.0% in the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after acquiring an additional 738,761 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.